- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01506466
Weight Variation During Chemotherapy in Breast Cancer Patients
Weight Variation and Mechanisms Involved, During Chemotherapy in Breast Cancer Patients
Weight variation has been reported as a side effect of chemotherapy treatment in early breast cancer patients. To date, there is growing evidence for an increased risk of relapse and death in these patients who gain or lose weight. However, causes of weight variation during chemotherapy and mechanisms involved in the poor prognosis have been little studied.
Thus, the investigators are conducting a prospective study to characterize weight variation in terms of body composition and to identify the mechanisms involved.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Clermont-Ferrand, Frankrig, 63000
- Centre Jean Perrin
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- menopausal women
- breast cancer
- patients requiring chemotherapy treatment
- WHO performance status 0-2
Exclusion Criteria:
- diabetics
- patients with metastases
- other cancer
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: additional examinations/measurements
|
blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from baseline in body composition
Tidsramme: within 2 weeks before chemotherapy; 1month after the last chemotherapy; and 6 months later.
|
within 2 weeks before chemotherapy; 1month after the last chemotherapy; and 6 months later.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in energy balance
Tidsramme: within 2 weeks before chemotherapy; 1month after the last chemotherapy; and 6 months later.
|
resting energy expenditure, physical activity, food records.
|
within 2 weeks before chemotherapy; 1month after the last chemotherapy; and 6 months later.
|
|
Change from baseline in muscle strength
Tidsramme: within 2 weeks before chemotherapy; 1month after the last chemotherapy; and 6 months later.
|
within 2 weeks before chemotherapy; 1month after the last chemotherapy; and 6 months later.
|
|
|
Change from baseline in biological factors (hormonal, inflammatory, lipid, growth factors)
Tidsramme: within 2 weeks before chemotherapy; 1month after the last chemotherapy; and 6 months later.
|
within 2 weeks before chemotherapy; 1month after the last chemotherapy; and 6 months later.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Xavier DURANDO, MD, PhD, Centre Jean Perrin
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2011-A00206-35
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
The First Affiliated Hospital of Xiamen UniversityIkke rekrutterer endnuLocally Advanced Breast Cancer (LABC)
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Beijing Bio-Targeting Therapeutics Technology Co...Trukket tilbage
-
Indonesia UniversityIkke rekrutterer endnuPræhabilitering | Postoperativ inflammation | Locally Advanced Breast Cancer (LABC)Indonesien
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
Atlas UniversityIkke rekrutterer endnuBrystkræft | Locally Advanced Breast Cancer (LABC)Tyrkiet (Türkiye)
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Second Affiliated Hospital, School of Medicine,...RekrutteringTNBC, Triple Negative Breast CancerKina
Kliniske forsøg med blood test/ additional measurement
-
Mayo ClinicNational Institute of Allergy and Infectious Diseases (NIAID); National...AfsluttetFungemia | Bakteriæmi | BlodbaneinfektionForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeLokalt avanceret uterin Corpus Leiomyosarcoma | Metastatisk uterin Corpus Leiomyosarcoma | Stadie III Uterine Corpus Leiomyosarcoma AJCC v8 | Stadie IV Uterine Corpus Leiomyosarcoma AJCC v8 | Uoperabelt uterin Corpus LeiomyosarcomaForenede Stater, Puerto Rico
-
National Cancer Institute (NCI)RekrutteringAkut myeloid leukæmi | Sekundær akut myeloid leukæmi | Akut myeloid leukæmi med KMT2A-omlægning | Akut myeloid leukæmi med NPM1-mutationForenede Stater